NCI Definition: A rare neuroectodermal tumor originating from olfactory receptor cells in the nasal cavity or paranasal sinuses. Microscopically, it is characterized by neuroblastic differentiation with occasional formation of rosettes. If the tumor is not resected at an early stage, the prognosis is usually poor. 
Olfactory neuroblastomas most frequently harbor alterations in SUFU, IKZF1, CTCF, CDKN2C, and YES1 .
CDKN2C Loss, YES1 Amplification, TRIM37 M556V, TP53 R306*, and TP53 Nonsense are the most common alterations in olfactory neuroblastoma .
There are 5 clinical trials for olfactory neuroblastoma, of which 5 are open and 0 are completed or closed. Of the trials that contain olfactory neuroblastoma as an inclusion criterion, 1 is phase 1 (1 open) and 4 are phase 2 (4 open).
Cisplatin, etoposide, and ifosfamide are the most common interventions in olfactory neuroblastoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.